<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01048333</url>
  </required_header>
  <id_info>
    <org_study_id>D5127C00001</org_study_id>
    <nct_id>NCT01048333</nct_id>
  </id_info>
  <brief_title>Evaluate Onset of Effect in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Formoterol Turbuhaler®</brief_title>
  <official_title>A Randomised, Placebo-controlled, Double-blind (Double-dummy Technique),Crossover, Multi-centre Study, to Evaluate Onset of Effect in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Formoterol Turbuhaler® 9 μg, Compared With Serevent® Diskus® 50 μg.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Primary objective is to evaluate time to onset of effect of formoterol, 9 μg single
           dose,compared with salmeterol, 50 μg single dose, in patients with moderate COPD.Forced
           Expiratory Volume in 1 second (FEV1) measured by spirometry 5 minutes postdose.

        -  Secondary efficacy variables: Average FEV1 during the first 15 minutes (area under the
           FEV1 curve from 0 to 15 minutes), Average FEV1 during 120 minutes (area under the FEV1
           curve from 0 to 120 minutes)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1(Forced Expiratory Volume in 1 Second) Measured by Spirometry 5 Minutes Post Dose</measure>
    <time_frame>Pre-dose and 5 minutes post-dose</time_frame>
    <description>FEV1(Forced Expiratory Volume in 1 second) measured by spirometry 5 minutes post dose, percentage change versus pre dose FEV1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average FEV1 During the First 15 Minutes Post Dose</measure>
    <time_frame>Pre dose and 15 minutes post dose</time_frame>
    <description>Average FEV1 during the first 15 minutes post dose, change versus pre dose FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average FEV1 During 120 Minutes Post Dose</measure>
    <time_frame>Pre dose and 120 minutes post dose</time_frame>
    <description>Average FEV1 during 120 minutes post dose, change versus pre dose FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Has Achieved at Least 12 % Increase in FEV1</measure>
    <time_frame>Pre dose, 5, 10, 15, 20, 30, 40, 50, 60 and 120 minutes post dose</time_frame>
    <description>Percentage of patients who has achieved at least 12 % increase in FEV1 at each time point between 5 to 120 minutes post dose, change versus pre dose FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>At baseline and at each day of treatment</time_frame>
    <description>Number of participants with at least 1 AE.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Formoterol, then Salmeterol, then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formoterol Turbuhaler 9 μg and Placebo Diskus first, then Salmeterol Diskus 50 μg and Placebo Turbuhaler, then Placebo Diskus and Placebo Turbuhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salmeterol, then Palcebo, then Formoterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Salmeterol Diskus 50 μg and Placebo Turbuhaler first, then Placebo Diskus and Placebo Turbuhaler, then Formoterol Turbuhaler 9 μg and Placebo Diskus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, then Formoterol, then Salmeterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo Diskus and Placebo Turbuhaler first,then Formoterol Turbuhaler 9 μg and Placebo Diskus, then Salmeterol Diskus 50 μg and Placebo Turbuhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formoterol, then Placebo, then Salmeterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formoterol Turbuhaler 9 μg and Placebo Diskus first, then Placebo Diskus and Placebo Turbuhaler, then Salmeterol Diskus 50 μg and Placebo Turbuhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salmeterol, then Formoterol, then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Salmeterol Diskus 50 μg and Placebo Turbuhaler first, then Formoterol Turbuhaler 9 μg and Placebo Diskus, then Placebo Diskus and Placebo Turbuhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, then Salmeterol, then Formoterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo Diskus and Placebo Turbuhaler first, then Salmeterol Diskus 50 μg and Placebo Turbuhaler, then Formoterol Turbuhaler 9 μg and Placebo Diskus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol</intervention_name>
    <description>Formoterol Turbuhaler 9 μg and Placebo Diskus</description>
    <arm_group_label>Formoterol, then Salmeterol, then Placebo</arm_group_label>
    <arm_group_label>Salmeterol, then Palcebo, then Formoterol</arm_group_label>
    <arm_group_label>Placebo, then Formoterol, then Salmeterol</arm_group_label>
    <arm_group_label>Formoterol, then Placebo, then Salmeterol</arm_group_label>
    <arm_group_label>Salmeterol, then Formoterol, then Placebo</arm_group_label>
    <arm_group_label>Placebo, then Salmeterol, then Formoterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salmeterol</intervention_name>
    <description>Salmeterol Diskus 50 μg and Placebo Turbuhaler</description>
    <arm_group_label>Formoterol, then Salmeterol, then Placebo</arm_group_label>
    <arm_group_label>Salmeterol, then Palcebo, then Formoterol</arm_group_label>
    <arm_group_label>Placebo, then Formoterol, then Salmeterol</arm_group_label>
    <arm_group_label>Formoterol, then Placebo, then Salmeterol</arm_group_label>
    <arm_group_label>Salmeterol, then Formoterol, then Placebo</arm_group_label>
    <arm_group_label>Placebo, then Salmeterol, then Formoterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Diskus and Placebo Turbuhaler</description>
    <arm_group_label>Formoterol, then Salmeterol, then Placebo</arm_group_label>
    <arm_group_label>Salmeterol, then Palcebo, then Formoterol</arm_group_label>
    <arm_group_label>Placebo, then Formoterol, then Salmeterol</arm_group_label>
    <arm_group_label>Formoterol, then Placebo, then Salmeterol</arm_group_label>
    <arm_group_label>Salmeterol, then Formoterol, then Placebo</arm_group_label>
    <arm_group_label>Placebo, then Salmeterol, then Formoterol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A clinical diagnosis of COPD according to GOLD guidelines, and current COPD symptoms

          -  A current or previous smoking history equivalent to 10 or more packs per year (1 pack
             year = 20 cigarettes smoked per day for one year).

          -  Documented use of a short-acting inhaled bronchodilator (β2-agonist or
             anticholinergics) as reliever medication.

        Exclusion Criteria:

          -  A history and/or current diagnosis of asthma.

          -  Patients who have experienced COPD exacerbation requiring hospitalisation and/or a
             course of antibiotics and/or a course of systemic steroid within 30 days (from end of
             exacerbation treatment) prior to Visit 1 and/or during the run-in period.

          -  A history and/or current diagnosis of atopic diseases such as allergic rhinitis or
             eczema before the age of 40.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario Cazzola, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Georgios Stratelis</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca MC Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bussolengo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cassano Delle Murge</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cava dei Tirreni</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Prato</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Linkoping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lulea</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Spain</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2010</study_first_submitted>
  <study_first_submitted_qc>January 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2010</study_first_posted>
  <results_first_submitted>September 9, 2011</results_first_submitted>
  <results_first_submitted_qc>September 25, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 25, 2012</results_first_posted>
  <last_update_submitted>September 25, 2012</last_update_submitted>
  <last_update_submitted_qc>September 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>Onset of effect</keyword>
  <keyword>COPD</keyword>
  <keyword>Oxis Turbuhaler</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients recruited at 14 clinics in 3 countries: Sweden (4 clinics); Italy (6 clinics); Spain (6 clinics)between January and May 2010</recruitment_details>
      <pre_assignment_details>141 patients enrolled; 32 excluded: 28 due to eligibility criteria not fulfilled and 4 for subject decision</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Formoterol, Then Salmeterol, Then Placebo</title>
          <description>Formoterol Turbuhaler 9 μg and Placebo Diskus first, then Salmeterol Diskus 50 μg and Placebo Turbuhaler, then Placebo Diskus and Placebo Turbuhaler</description>
        </group>
        <group group_id="P2">
          <title>Salmeterol, Then Palcebo, Then Formoterol</title>
          <description>Salmeterol Diskus 50 μg and Placebo Turbuhaler first, then Placebo Diskus and Placebo Turbuhaler, then Formoterol Turbuhaler 9 μg and Placebo Diskus</description>
        </group>
        <group group_id="P3">
          <title>Placebo, Then Formoterol, Then Salmeterol</title>
          <description>Placebo Diskus and Placebo Turbuhaler first,then Formoterol Turbuhaler 9 μg and Placebo Diskus, then Salmeterol Diskus 50 μg and Placebo Turbuhaler</description>
        </group>
        <group group_id="P4">
          <title>Formoterol, Then Placebo, Then Salmeterol</title>
          <description>Formoterol Turbuhaler 9 μg and Placebo Diskus first, then Placebo Diskus and Placebo Turbuhaler, then Salmeterol Diskus 50 μg and Placebo Turbuhaler</description>
        </group>
        <group group_id="P5">
          <title>Salmeterol, Then Formoterol, Then Placebo</title>
          <description>Salmeterol Diskus 50 μg and Placebo Turbuhaler first, then Formoterol Turbuhaler 9 μg and Placebo Diskus, then Placebo Diskus and Placebo Turbuhaler</description>
        </group>
        <group group_id="P6">
          <title>Placebo, Then Salmeterol, Then Formoterol</title>
          <description>Placebo Diskus and Placebo Turbuhaler first, then Salmeterol Diskus 50 μg and Placebo Turbuhaler, then Formoterol Turbuhaler 9 μg and Placebo Diskus</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="17"/>
                <participants group_id="P6" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="17"/>
                <participants group_id="P6" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Wash-Out Period 1 of 2 - 7 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="17"/>
                <participants group_id="P6" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="17"/>
                <participants group_id="P6" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="17"/>
                <participants group_id="P6" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="17"/>
                <participants group_id="P6" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Wash-Out Period 2 of 2 - 7 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="17"/>
                <participants group_id="P6" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="17"/>
                <participants group_id="P6" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="17"/>
                <participants group_id="P6" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="17"/>
                <participants group_id="P6" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>Includes all 3 arms : Formoterol, Salmeterol and Placebo.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="109"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.5" lower_limit="41.0" upper_limit="84.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>FEV1(Forced Expiratory Volume in 1 Second) Measured by Spirometry 5 Minutes Post Dose</title>
        <description>FEV1(Forced Expiratory Volume in 1 second) measured by spirometry 5 minutes post dose, percentage change versus pre dose FEV1</description>
        <time_frame>Pre-dose and 5 minutes post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Formoterol</title>
            <description>Formoterol Turbuhaler 9 mcg</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Serevent Diskus (salmeterol) 50 mcg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo salmeterol Diskus and Placebo Turbuhaler</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1(Forced Expiratory Volume in 1 Second) Measured by Spirometry 5 Minutes Post Dose</title>
          <description>FEV1(Forced Expiratory Volume in 1 second) measured by spirometry 5 minutes post dose, percentage change versus pre dose FEV1</description>
          <units>percentage change</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.072" lower_limit="1.055" upper_limit="1.088"/>
                    <measurement group_id="O2" value="1.041" lower_limit="1.025" upper_limit="1.057"/>
                    <measurement group_id="O3" value="1.007" lower_limit="0.992" upper_limit="1.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average FEV1 During the First 15 Minutes Post Dose</title>
        <description>Average FEV1 during the first 15 minutes post dose, change versus pre dose FEV1</description>
        <time_frame>Pre dose and 15 minutes post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Formoterol</title>
            <description>Formoterol Turbuhaler 9 mcg</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Serevent Diskus (salmeterol) 50 mcg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo salmeterol Diskus and Placebo Turbuhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Average FEV1 During the First 15 Minutes Post Dose</title>
          <description>Average FEV1 during the first 15 minutes post dose, change versus pre dose FEV1</description>
          <units>percentage change</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.064" lower_limit="1.052" upper_limit="1.077"/>
                    <measurement group_id="O2" value="1.041" lower_limit="1.030" upper_limit="1.053"/>
                    <measurement group_id="O3" value="1.012" lower_limit="1.001" upper_limit="1.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average FEV1 During 120 Minutes Post Dose</title>
        <description>Average FEV1 during 120 minutes post dose, change versus pre dose FEV1</description>
        <time_frame>Pre dose and 120 minutes post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Formoterol</title>
            <description>Formoterol Turbuhaler 9 mcg</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Serevent Diskus (salmeterol) 50 mcg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo salmeterol Diskus and Placebo Turbuhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Average FEV1 During 120 Minutes Post Dose</title>
          <description>Average FEV1 during 120 minutes post dose, change versus pre dose FEV1</description>
          <units>percentage change</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.096" lower_limit="1.079" upper_limit="1.112"/>
                    <measurement group_id="O2" value="1.082" lower_limit="1.066" upper_limit="1.098"/>
                    <measurement group_id="O3" value="1.014" lower_limit="0.999" upper_limit="1.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Has Achieved at Least 12 % Increase in FEV1</title>
        <description>Percentage of patients who has achieved at least 12 % increase in FEV1 at each time point between 5 to 120 minutes post dose, change versus pre dose FEV1</description>
        <time_frame>Pre dose, 5, 10, 15, 20, 30, 40, 50, 60 and 120 minutes post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Formoterol</title>
            <description>Formoterol Turbuhaler 9 mcg</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Serevent Diskus (salmeterol) 50 mcg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo salmeterol Diskus and Placebo Turbuhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Has Achieved at Least 12 % Increase in FEV1</title>
          <description>Percentage of patients who has achieved at least 12 % increase in FEV1 at each time point between 5 to 120 minutes post dose, change versus pre dose FEV1</description>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1"/>
                    <measurement group_id="O2" value="9.2"/>
                    <measurement group_id="O3" value="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.0"/>
                    <measurement group_id="O2" value="17.6"/>
                    <measurement group_id="O3" value="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.8"/>
                    <measurement group_id="O2" value="23.9"/>
                    <measurement group_id="O3" value="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4"/>
                    <measurement group_id="O2" value="27.5"/>
                    <measurement group_id="O3" value="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.4"/>
                    <measurement group_id="O2" value="32.1"/>
                    <measurement group_id="O3" value="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.1"/>
                    <measurement group_id="O2" value="36.7"/>
                    <measurement group_id="O3" value="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.7"/>
                    <measurement group_id="O2" value="40.4"/>
                    <measurement group_id="O3" value="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.6"/>
                    <measurement group_id="O2" value="43.1"/>
                    <measurement group_id="O3" value="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6"/>
                    <measurement group_id="O2" value="48.6"/>
                    <measurement group_id="O3" value="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.090</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.31</ci_lower_limit>
            <ci_upper_limit>3.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>6.534</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.55</ci_lower_limit>
            <ci_upper_limit>12.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>3.127</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.77</ci_lower_limit>
            <ci_upper_limit>5.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Number of participants with at least 1 AE.</description>
        <time_frame>At baseline and at each day of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Formoterol</title>
            <description>Formoterol Turbuhaler 9 mcg</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Serevent Diskus (salmeterol) 50 mcg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo salmeterol Diskus and Placebo Turbuhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Number of participants with at least 1 AE.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Formoterol</title>
          <description>Formoterol Turbuhaler 9 mcg</description>
        </group>
        <group group_id="E2">
          <title>Salmeterol</title>
          <description>Serevent Diskus (salmeterol) 50 mcg</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo salmeterol Diskus and Placebo Turbuhaler</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>Astra Zeneca</organization>
      <phone>+44 1509 645895</phone>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

